Skip to content
10-Q

Quarterly Report

PHARMAGEN, INC.

0001477932-14-002552

← back to feed
Filed
May 15, 2014 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2014 · May 12, 2014 517.08M sh
Capex Q1 2014 · Mar 31, 2014 $62.17K
Capex Q1 2014 · Mar 31, 2013 $16.26K
Operating Cash Flow Q1 2014 · Mar 31, 2014 $48.36K
Operating Cash Flow Q1 2014 · Mar 31, 2013 −$160.62K
Short Term Debt Q1 2014 · Mar 31, 2014 $520K
Short Term Debt Q1 2014 · Dec 31, 2013 $500K
Cash And Equivalents Q1 2014 · Mar 31, 2014 $264.67K
Cash And Equivalents Q1 2014 · Dec 31, 2013 $225.98K
Cash And Equivalents Q1 2014 · Mar 31, 2013 $646.96K
Cash And Equivalents Q1 2014 · Dec 31, 2012 $322.56K
Stockholders Equity Q1 2014 · Mar 31, 2014 −$8.03M
Stockholders Equity Q1 2014 · Dec 31, 2013 −$7.71M
Current Liabilities Q1 2014 · Mar 31, 2014 $8.29M
Current Liabilities Q1 2014 · Dec 31, 2013 $8.08M
Total Liabilities Q1 2014 · Mar 31, 2014 $9.08M
Total Liabilities Q1 2014 · Dec 31, 2013 $8.87M
Current Assets Q1 2014 · Mar 31, 2014 $837K
Current Assets Q1 2014 · Dec 31, 2013 $879.31K
Total Assets Q1 2014 · Mar 31, 2014 $1.28M
Total Assets Q1 2014 · Dec 31, 2013 $1.28M
Sga Expense Q1 2014 · Mar 31, 2014 $401.03K
Sga Expense restated Q1 2014 · Mar 31, 2013 $529.06K
Net Income Q1 2014 · Mar 31, 2014 −$712.6K
Net Income Q1 2014 · Mar 31, 2013 −$841.79K
Operating Income Q1 2014 · Mar 31, 2014 −$410.52K
Operating Income restated Q1 2014 · Mar 31, 2013 −$327.51K
Gross Profit Q1 2014 · Mar 31, 2014 $736.47K
Gross Profit restated Q1 2014 · Mar 31, 2013 $1.03M
Cost Of Revenue Q1 2014 · Mar 31, 2014 $582.99K
Cost Of Revenue restated Q1 2014 · Mar 31, 2013 $686.54K